Camber Pharmaceuticals Inc
Chris Trotta is a Contracts and Pricing Analyst at Camber Pharmaceuticals Inc since April 2023, previously serving as a Creative Services Coordinator at MJH Life Sciences™ from May 2022 to November 2022. Prior experience includes working as a Certificates Control Assistant at Fross Zelnick Lehrman & Zissu from February 2021 to March 2022. Chris Trotta holds a Bachelor's degree from Rowan University, attained between September 2016 and May 2020.
Camber Pharmaceuticals Inc
Camber is made up of three groups with one common goal: to be the best generics company in the industry. Camber Pharmaceuticals is rapidly growing and had an industry-leading 28 product approvals in 2022. With the support of our parent company, Hetero, we are poised to have a record number of product approvals and launches in 2023. Hetero, a world leader in API production and vertical manufacturing, is the foundation upon which Camber has maintained a 99% service level for our customers for the past two years. Hetero is investing over $250 million in the next three years in Camber products. The research and development team consists of over 1,000 scientists working to expand the types of drugs Camber offers, including novel delivery systems and complex molecules.